Six promising companies will receive additional funding of €1.3 ($1.5) million each from BioInnovation Institute (BII) to help them bring their technologies and products closer to market. 

The six companies – PanTarg, 3Sonic, Inia Biosciences, Yngvi Bio, Proxi Biotech and Sagava – have all previously received €0.5 million in funding from BII. With the new funds allocated, each company has now received a total of €1.8 million. 

The continued funding also comes with access to BII’s innovation platform in the heart of Copenhagen. Here, the companies can gain access to advanced laboratory facilities, a global network of investors, advisors and strategic partners, as well as expertise in business development and commercialisation. 

Three of the six are focused on the development of new medicines, while the others target imaging, agriculture and maritime sustainability. 

Trine Bartholdy, Chief Business Officer at BII, said: “The six companies have demonstrated strong potential and have already taken important steps from promising research to developing solutions that can make a real difference. With continued funding, they have the opportunity to accelerate their development and focus even more on their path towards the market. 

“We see significant potential in all six companies, and our role is to help them turn their technologies into sustainable businesses and products that can create value for patients, society and investor.” 

The three drug discovery companies 
  • PanTarg is developing a new type of antibody-based cancer treatment that combines two targeted attacks in a single therapy. The company’s technology is particularly aimed at aggressive cancers, including pancreatic cancer, where there remains a significant need for more effective treatments. PanTarg is a spin-out from the University of Copenhagen and Rigshospitalet, founded by researchers Lars Engelholm and Virginia Metrangolo. The company is also a partner in a major research project for the period 2026–2030, supported by the Innovation Fund Denmark, focusing on enabling drugs to cross the blood-brain barrier. 
  • Inia Biosciences is developing new treatments for inflammatory diseases, with psoriasis as its initial focus. The company is working to transform the treatment of inflammation and develop more effective therapeutic solutions for patients suffering from inflammatory diseases. Inia Biosciences originally emerged from the innovation ecosystems in Boston and Oxford. 
  • Proxi Biotech is developing a novel vaccine-based immunotherapy for recurrent bacterial infections. The company’s lead candidate targets recurrent infections caused by Clostridium difficile, which can affect patients repeatedly and become chronic. The technology is intended to provide an alternative to treatments such as faecal microbiota transplantation. Proxi Biotech is a spin-out from Statens Serum Institut (SSI), Denmark’s national public health institute.